SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?


To: Rob L. who wrote (1097)12/10/1998 11:32:00 AM
From: Anthony Wong  Read Replies (1) | Respond to of 1580
 
Merck & Co. Cut to 'Hold' at Warburg Dillon Read Target $160

Princeton, New Jersey, Dec. 10 (Bloomberg Data) -- Merck & Co., Inc. (MRK US) was downgraded to ''hold'' from ''buy'' by analyst Jerome R. Brimeyer at Warburg Dillon Read Inc.. The 12-month target price is $160.00 per share.



To: Rob L. who wrote (1097)12/10/1998 11:36:00 AM
From: Anthony Wong  Respond to of 1580
 
Merck & Co. Reiterated 'Strong Buy' at CIBC Oppenheimer Target $175

Princeton, New Jersey, Dec. 10 (Bloomberg Data) -- Merck & Co., Inc. (MRK US) was reiterated ''strong buy'' by analyst Steven B. Gerber Md at CIBC Oppenheimer. The 12-month target price is $175.00 per share.